BRIEF OVERVIEW
Venture Corporation Limited delivered a strong set of 3Q26 results, with 9M26 revenue exceeding expectations at 81% of FY26 estimated forecasts, while profit after tax was within expectations at 73%. Third-quarter earnings jumped 22% year on year to S$67.8 million, with AI-related products — namely networking cards, semiconductors, transceivers and test equipment — driving revenue growth of around 38% year on year. Management guidance pointed to robust demand, with growth across multiple domains and life science beginning to recover. Phillip Securities Research expects FY27 estimated growth to be even stronger, driven by consumer lifestyle products.
INVESTMENT POSITIVES
Strongest Growth in 16 Quarters
Venture’s 3Q26 revenue surged 26% year on year to S$790 million, marking the strongest growth in 16 quarters. Growth was led by Portfolio B products, specifically test and measurement, networking and communications, and semiconductors. This is a noteworthy inflection point for the company, with the breadth and pace of recovery signalling a return to meaningful earnings growth after an extended period of more subdued performance.
AI-Related Products Driving Revenue Momentum
AI-related products were central to the revenue acceleration. Networking cards, semiconductors, transceivers and test equipment collectively drove revenue growth of around 38% year on year in the quarter. Venture is riding on the global data centre build-out with new products, with semiconductor and power equipment identified as key products in this growth cycle. The company’s positioning in these high-growth areas underpins the analyst’s conviction that earnings growth is returning to Venture.
Broad-Based Demand Across Multiple Domains
Management highlighted robust demand across multiple domains, not limited to AI-related segments. The life science domain is beginning to recover, with genomic sequencing equipment identified as a key growth product. The bottoming of life science demand represents an upside surprise for the business, providing an additional avenue for revenue diversification and recovery.
New Products and Capacity Expansion Supporting Outlook
The ramp-up of new products supporting data centre infrastructure, together with new capacity in Malaysia, is driving earnings growth. Additionally, the launch of a new consumer lifestyle product with a narrow supply base is expected to become an added growth driver for FY27 estimated. The analyst expects FY27 estimated growth to be even stronger than FY26, supported by these new product launches and expanded production capacity.
INVESTMENT CHALLENGES
We identified no negatives for Venture Corporation in this quarter. The absence of stated negatives reflects the broad-based strength in demand and the positive trajectory across multiple business domains.
OUTLOOK
Venture Corporation is well positioned to benefit from the ongoing global data centre build-out, with new products across semiconductors and power equipment forming the core of its growth engine. The expected launch of a new consumer lifestyle product with a narrow supply base adds a further growth driver for FY27 estimated. The recovery in life science demand, particularly in genomic sequencing equipment, provides an upside surprise to the earnings outlook. With new manufacturing capacity in Malaysia coming on stream and robust demand across multiple product domains, the analyst sees a constructive outlook for the company in the near to medium term.
RECOMMENDATION AND TARGET PRICE
Phillip Securities Research maintains its BUY recommendation on Venture Corporation with FY26 estimated earnings unchanged. However, the target price has been lowered to S$19.50 from S$22.10. The reduction reflects a lower price-to-earnings multiple of 22 times FY26 estimated earnings, down from 25 times previously, brought in line with US peers. Despite the lower target price, the analyst believes earnings growth is returning to Venture, supported by the ramp-up of new data centre infrastructure products and new capacity in Malaysia.
This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.
Frequently Asked Questions
Q: What is our recommendation and target price for Venture Corporation?
A: Phillip Securities Research maintains a BUY recommendation with a lowered target price of S$19.50, down from S$22.10 previously.
Q: How did Venture Corporation perform in 3Q26?
A: 3Q26 revenue surged 26% year on year to S$790 million, the strongest growth in 16 quarters, while earnings jumped 22% year on year to S$67.8 million.
Q: What drove the strong revenue growth?
A: Growth was led by Portfolio B products, specifically test and measurement, networking and communications, and semiconductors. AI-related products, including networking cards, semiconductors, transceivers and test equipment, drove revenue growth of around 38% year on year.
Q: Why was the target price reduced despite a BUY recommendation being maintained?
A: The price-to-earnings multiple was lowered from 25 times to 22 times FY26 estimated earnings, brought in line with US peers, resulting in the target price reduction from S$22.10 to S$19.50.
Q: Were there any negatives identified by the analyst?
A: No negatives were identified for Venture Corporation in this quarter.
Q: What is the outlook for FY27?
A: We expect FY27 estimated growth to be even stronger than FY26, driven by the launch of a new consumer lifestyle product with a narrow supply base, continued data centre infrastructure demand, and recovery in life science.
Q: How is the life science segment performing?
A: Life science demand is beginning to recover, with genomic sequencing equipment identified as a key growth product. The bottoming of life science demand is considered an upside surprise.
Q: How did 9M26 results compare to full-year estimates?
A: 9M26 revenue exceeded expectations at 81% of FY26 estimated forecasts, while profit after tax was within expectations at 73%.
Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.
Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.
Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.
The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.
Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
This advertisement has not been reviewed by the Monetary Authority of Singapore.





